All In Biotech

Drug Trial Radar · NCT05359445

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER®), as Monotherapy or in Combination With Checkpoint Inhibitor in Patients With Recurrent and/or Refractory Solid Tumors.

Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

95

Planned (sponsor's estimate)

Start

May 19, 2022

Primary completion

Mar 18, 2026

Study completion Dec 2029

Sponsor

Lead sponsor
Immatics Biotechnologies GmbHIndustry
Sponsor type
Industry
First posted
May 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety, tolerability and initial anti-tumor activity of IMA401 as monotherapy or in combination with checkpoint inhibitor in patients with recurrent and/or refractory solid tumors. Patients' HLA status and expression of the MAGE-A4 and/or MAGE-A8 target in the tumor must be confirmed. Primary objective: * To determine the maximum tolerated dose and/or recommended dose for extension for IMA401 as monotherapy and in combination with pembrolizumab Secondary objectives: * To characterize the safety and tolerability of IMA401 as monotherapy and in combination with pembrolizumab * To evaluate initial anti-tumor activity of IMA401 as monotherapy and in combination with pembrolizumab * To describe the pharmacokinetics of IMA401 as monotherapy and in combination with pembrolizumab

Conditions

  • Refractory Cancer
  • Recurrent Cancer
  • Solid Tumor, Adult
  • Cancer

Interventions

  • IMA401 (Phase Ia)Biological

    Intravenous infusions in escalating dose levels

  • Pembrolizumab (Phase Ia)Biological

    Intravenous infusions in escalating dose levels for combination of IMA 401 and Pembrolizumab

  • IMA 401 (Phase Ib)Biological

    Treatment at recommended dose for extension (RDE)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with dose limiting toxicitiesTime frame: 44 months

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Charité Universitaetsmedizin Berlin KöR, Klinik fuer Haematologie und Onkologie

    Berlin, Germany

  • Universitaetsklinikum Freiburg, Zentralklinikum, Klinik fuer Innere Medizin I

    Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • Universitaetsklinikum Heidelberg AöR, Nationales Zentrum fuer Tumorkrankheiten

    Heidelberg, Baden-Wurttemberg, Germany

  • Thoraxklinik Heidelberg gGmbH, Studienzentrum Thoraxonkologie

    Heidelberg, Baden-Wurttemberg, Germany

  • Universitaetsklinikum Tuebingen AöR, Comprehensive Cancer Center Tuebingen

    Tübingen, Baden-Wurttemberg, Germany

  • Universitaetsklinikum Ulm AöR, ECTU-Early clinical Trials Unit Universitaetsklinikum Ulm Comprehensive Cancer Center Ulm_CCCU

    Ulm, Baden-Wurttemberg, Germany

  • Universitaetsklinikum Erlangen AöR, Interdisciplinary Clinical Trial Unit with ECTU

    Erlangen, Bavaria, Germany

  • Klinikum rechts der Isar der TU Muenchen AöR, Klinik und Poliklinik fuer Innere Medizin III

    Munich, Bavaria, Germany

  • Klinikum Nuernberg, Klinik fuer Innere Medizin 5, Abteilung Onkologie/Haematologie

    Nuremberg, Bavaria, Germany

  • Universitaetsklinikum Regensburg AöR, Klinik fuer Innere Medizin 3

    Regensburg, Bavaria, Germany

  • Universitaetsklinikum Wuerzburg AöR, Interdisziplinaeres Studienzentrum mit ECTU

    Würzburg, Bavaria, Germany

  • Goethe Universitaetsklinikum Frankfurt AöR, Medizinische Klinik II

    Frankfurt am Main, Hesse, Germany

  • Medizinische Hochschule Hannover, Klinik fuer Haematologie, Haemostaseologie, Onkologie und Stammzelltransplantation

    Hanover, Lower Saxony, Germany

  • Universitätsklinikum Bonn AöR, Medizinische Klinik IIII

    Bonn, North Rhine-Westphalia, Germany

  • Marien Hospital Duesseldorf GmbH, Klinik fuer Onkologie/Haematologie und Palliativmedizin

    Düsseldorf, North Rhine-Westphalia, Germany

  • Universitaetsklinikum Muenster AöR, Medizinische Klinik A

    Münster, North Rhine-Westphalia, Germany

  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR, III. Medizinische Klinik

    Mainz, Rhineland-Palatinate, Germany

  • Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III

    Chemnitz, Saxony, Germany

  • Universitaetsklinikum C. - G. - Carus Dresden, Technische Universitaet Dresden AöR, NCT/UCC Early Clinical Trial Unit

    Dresden, Saxony, Germany

  • Universitaet Leipzig, Universitaeres Krebszentrum Leipzig (UCCL)

    Leipzig, Saxony, Germany

  • Universitaetsklinikum Schleswig- Holstein, Campus Kiel, Medizinische Klinik II Haematologie und Onkologie, Karl-Lennert Tumorzentrum

    Kiel, Schleswig-Holstein, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.